Orchid Pharma Limited has submitted its quarterly compliance certificate to the National Stock Exchange and BSE Limited, confirming adherence to depositories regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory documentation under SEBI Regulation 74(5) on April 9, 2026.

Regulatory Compliance Documentation

The confirmation certificate was issued by Abhipra Capital Limited, the company's registrar and share transfer agent, on April 1, 2026. This certificate validates compliance with the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, as amended, for Quarter-IV of Financial Year 2025-26.

Certificate Confirmations

Abhipra Capital Limited confirmed several key compliance aspects in their certificate. The registrar verified that securities received from depository participants for dematerialization during the quarter were properly confirmed to the depositories. Additionally, they confirmed that securities comprised in the certificates have been listed on stock exchanges where previously issued securities are listed.

The certificate also validates that security certificates received for dematerialization were mutilated and cancelled after due verification by depository participants. The registrar confirmed that depository names were substituted in the register of members as registered owners within the mandated 15-day timeframe.

Filing Details and Authorization

Company Secretary and Compliance Officer Kapil Dayya (Membership No: F10698) signed and submitted the compliance documentation on behalf of Orchid Pharma Limited. The submission was made to both major stock exchanges where the company's shares are listed.

Depository Notification

Copies of the compliance certificate were also forwarded to both major depositories in India. National Securities Depository Limited and Central Depository Services (India) Limited received the documentation as part of the regulatory filing process, ensuring comprehensive compliance across all relevant regulatory bodies.

The filing demonstrates Orchid Pharma's commitment to maintaining regulatory compliance and transparent reporting practices in accordance with SEBI guidelines for depositories and participants regulations.

Orchid Pharma Limited has announced an investor roadshow scheduled for April 10, 2026, in Gurugram. The pharmaceutical company informed the National Stock Exchange of India Limited and BSE Limited about this development on April 07, 2026, under Regulation 30 of SEBI listing requirements.

Roadshow Details

The investor roadshow will feature Mr. Mridul Dhanuka, Whole Time Director of Orchid Pharma Limited, who will participate in the scheduled meeting with investors.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The company has emphasized that no unpublished price sensitive information is proposed to be shared during the investor meet.

Important Considerations

Orchid Pharma Limited has noted that the roadshow schedule may undergo changes due to unforeseen exigencies on the part of investors or the company. Any such changes will be communicated accordingly. The notification was signed by Manish Dhanuka, Managing Director, on April 07, 2026.